Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10137788 | 0.91 | AKR1B1 (0.57) | CYP1A2AKR1B1KDM4ETDP1 | |
| SCHEMBL21100153 | 0.91 | L3MBTL1 (0.47) | CYP1A2AKR1B1TSHRL3MBTL1ALDH1A1 | |
| SCHEMBL17058915 | 0.89 | CYP1A2 (0.45) | CYP1A2AKR1B1TSHRL3MBTL1KDM4E | |
| SCHEMBL12158563 | 0.87 | CTBP2 (0.53) | CYP1A2ALDH1A1KDM4EGAACTBP2 | |
| SCHEMBL8088739 | 0.87 | AKR1B1 (0.63) | CYP1A2AKR1B1TSHRGABRA1GABRB2 | |
| SCHEMBL888636 | 0.86 | CYP1A2 (0.42) | CYP1A2TSHRALDH1A1 | |
| SCHEMBL26710859 | 0.86 | CYP1A2 (0.42) | CYP1A2TSHRL3MBTL1ALDH1A1MEN1 | |
| SCHEMBL24309293 | 0.85 | CYP1A2 (0.45) | CYP1A2TSHRALDH1A1KMT2A | |
| SCHEMBL9911546 | 0.85 | CTBP2 (0.51) | CYP1A2ALDH1A1CTBP2KMT2A | |
| SCHEMBL24260607 | 0.85 | CYP1A2 (0.45) | CYP1A2AKR1B1TSHRALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689430-B2 | Insulin receptor partial agonists | MERCK SHARP & DOHME CORP. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190177393-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177393-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | CYP1A2 3000/4885AKR1B1 1623/4885TSHR 27/4885 |
| US-10689430-B2 | Insulin receptor partial agonists | INSR, GPR119, IRS1 | CYP1A2 3000/4885AKR1B1 1623/4885TSHR 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.